News

Shares of Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) are down nearly 2% after the company delivered its third-quarter earnings report. The news wasn't particularly bad, although there was a

Pharmaceutical stocks aren't having quite the banner year they've had in the past. Notably, two large pharmaceutical companies recently plunged to 52-week lows on their earnings results. Many

Pharmaceutical stocks aren't having quite the banner year they've had in the past. Notably, two large pharmaceutical companies recently plunged to 52-week lows on their earnings results. Many

Because earnings guidance is a company's best effort to forecast its earnings, it is a leading cause of share price movement. However, simply raising or lowering guidance is not enough to move a

Shares of Johnson & Johnson (NYSE: JNJ) slid 4.84% lower the week ending October 27, as the company’s subsidiary LTL Management is facing a raft of lawsuits pertaining to talc in its baby powder. 

Shares of Johnson & Johnson (NYSE: JNJ) slid 4.84% lower the week ending October 27, as the company’s subsidiary LTL Management is facing a raft of lawsuits pertaining to talc in its baby powder. 

Shares of AbbVie Inc. (NYSE: ABBV) have been under pressure for nearly two years because of mounting fears about the patent cliff. The patent cliff impacted the company’s results but has done

Results from Johnson & Johnson (NYSE: JNJ) and Abbott Laboratories (NYSE: ABT) foreshadow good news for MedTech investors. Both companies outperformed on the top and bottom lines, driven by broad

Abbott Laboratories (NYSE: ABT) share price has trended lower for nearly 2 years, but that trend is over. The impact of COVID on sales and the post-COVID letdown were cause enough for the market

Walgreens Boots Alliance (NASDAQ: WBA) shares are down significantly over the past two years and may fall further. The company's turnaround efforts are slowly taking hold, and the impact of

Over the last several months, many sectors, industries, and the overall market have come under pressure and experienced significant outflows and waves of selling. 

During this period, over the

Over the last several months, many sectors, industries, and the overall market have come under pressure and experienced significant outflows and waves of selling. 

During this period, over the

Over the last several months, many sectors, industries, and the overall market have come under pressure and experienced significant outflows and waves of selling. 

During this period, over the

Over the last month, the overall market has experienced significant selling amid increased uncertainty. The S&P 500 ETF Trust (NYSE: SPY) has traded almost 5.5% lower in that period, and wherever

Over the last month, the overall market has experienced significant selling amid increased uncertainty. The S&P 500 ETF Trust (NYSE: SPY) has traded almost 5.5% lower in that period, and wherever

The Health Care Select Sector SPDR Fund (NYSEARCA: XLV) is down 2.40% in the past three months, and down 4.67% year-to-date. 

With the current sector-wide downturn, it’s not surprising that

The Health Care Select Sector SPDR Fund (NYSEARCA: XLV) is down 2.40% in the past three months, and down 4.67% year-to-date. 

With the current sector-wide downturn, it’s not surprising that

The Health Care Select Sector SPDR Fund (NYSEARCA: XLV) is down 2.40% in the past three months, and down 4.67% year-to-date. 

With the current sector-wide downturn, it’s not surprising that

What started out to be a promising third quarter for U.S. stocks turned into a dud. On the backs of artificial intelligence (AI) excitement, the S&P 500 stormed out of the gates in July only to

If you had to guess the largest S&P company outside of big tech stocks or Berkshire Hathaway Inc. (NYSE: BRK.B), would you guess a healthcare stock? 

Health insurer UnitedHealth Group Inc. (NYSE:

While the direction of the stock markets is unpredictable, the growth of the aging population is entirely predictable. Along with an aging population come additional healthcare, beauty and

It’s not often that you see a company whose main product comes with a price tag of over $2 million, but that’s the case with biotechs BioMarin Pharmaceutical (NASDAQ: BMRN) and Sarepta

If you want to get an isolated view of a constructive base taking shape in a strong stock, take a look at the Argenix SE (NASDAQ: ARGX) chart. 

The stock gapped up nearly 28% on July 17, after

If you’re looking for a sector that’s on sale, look to healthcare. The Health Care Select Sector SPDR Fund (NYSEARCA: XLV) is down 2.50% in the past month, lagging the S&P 500. 

The top

If you’re looking for a sector that’s on sale, look to healthcare. The Health Care Select Sector SPDR Fund (NYSEARCA: XLV) is down 2.50% in the past month, lagging the S&P 500. 

The top